Kimberly-Clark Corporation research snapshot
KMB AI stock analysis currently reads Kimberly-Clark as a defensive consumer staples business with durable brands, high dividend relevance, improving volume-plus-mix execution, and a major strategic overhang from the pending Kenvue acquisition. The business is easier to underwrite than a cyclical stock, but the investment case is not simple: the stock has rebounded from its 2026 lows, free cash flow yield is reasonable, and the Kenvue transaction could either widen the health and wellness platform or add leverage, integration complexity, and litigation exposure.
Current price
$114.74
Market cap
$38.09 billion
AI score
67 / 100
Rating
Defensive income stock with integration risk
Trend status
Sharp rebound above moving averages, still below prior high
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Kimberly-Clark sells repeat-purchase personal care and tissue products across essential household categories where brand trust, availability, and habit matter. | High |
| Moat | The moat is based on brand equity, retail shelf presence, supply chain scale, consumer habit, and innovation in diapers, tissue, feminine care, and adult care. | Medium-high |
| Management | Mike Hsu is leading a multi-year transformation and the pending Kenvue acquisition, so capital allocation judgment now matters more than routine staples execution. | Medium |
| Financial trend | FY2025 net sales were $16.447 billion, net income to common was $2.021 billion, and Q1 2026 continuing operations sales rose 2.7% to $4.2 billion. | High |
| Valuation | At $114.74, KMB trades near 18.0x TTM EPS, 20.8x TTM free cash flow per share, and offers a dividend yield near 4.5%. | Medium-high |
| Technical trend | KMB has moved above its 20-day, 50-day, and 200-day moving averages, but RSI and stochastic readings suggest the rebound is no longer early. | Medium |
| Risk level | Risk is moderate for the legacy business and higher for the combined-company thesis because the Kenvue deal adds execution, regulatory, debt, and litigation variables. | Medium-high |
| AI confidence | The descriptive data confidence is high, while the return forecast is scenario-based and sensitive to EPS growth, multiple, and Kenvue close conditions. | High data confidence |
| Investment certainty | KMB has stronger defensive certainty than growth certainty. The stock may suit income-oriented analysis, but the pending deal lowers certainty until financing and integration details mature. | Medium |
KMB AI stock forecast
The KMB AI stock forecast should be read as scenario math, not a fixed price prediction. Using TTM EPS near $6.37, a July 8, 2026 price near $114.74, and a three-year framework, the tested range spans a bearish area near $84, a base area near $115, and a bullish area near $143 before dividends. The dividend is material, but the equity outcome depends on EPS growth, consumer staples multiples, and whether the Kenvue transaction creates more value than complexity.
$140 to $145
More likely if organic sales stay positive, personal care volume-plus-mix improves, productivity offsets input cost pressure, Kenvue closes with credible synergy execution, and the market pays about 20x earnings for a larger health and wellness platform.
$112 to $116
More likely if EPS compounds around 2% annually, dividends remain covered, the legacy KMB business grows slowly, and valuation stays near a high-teens earnings multiple while investors wait for integration proof.
$82 to $86
More likely if pricing power weakens, private label gains share, pulp or freight costs rise, Kenvue adds litigation or leverage concerns, or higher real rates compress defensive staples multiples toward the mid-teens.
KMB AI technical analysis
KMB AI technical analysis is constructive after a sharp rebound, but not low-risk. As of the July 8, 2026 data cutoff, KMB traded near $114.74, above several moving-average references and well above the 52-week low near $92.42, while still below the 52-week high near $137.46. Momentum is positive, but overbought indicators make risk controls important.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $114.74 | StockAnalysis and market data showed KMB around $114 to $115 on July 8, 2026. |
| Near support | $104 to $106 | This area covers recent 20-day and 200-day moving-average references from Barchart and Financhill. A break back below it would weaken rebound quality. |
| Deeper support | $99 to $101 | This zone covers recent 50-day moving-average references and the prior consolidation area. |
| Near resistance | $116 to $120 | KMB recently traded near this rebound zone. A clean move above it needs confirmation rather than a thin defensive rotation. |
| Major resistance | $137 to $138 | The 52-week high area near $137.46 remains the larger overhead reference. |
| 50-day SMA | $100.57 | Barchart technical data showed KMB above its 50-day simple moving average. |
| 200-day SMA | $104.83 | Barchart technical data showed KMB above its 200-day simple moving average. |
| Momentum | RSI near 70 | Barchart reported 14-day relative strength near 70, which supports momentum but also warns against chasing without a plan. |
| Volume | Confirm breakout | A move through the $116 to $120 area is more useful if volume stays above recent averages rather than fading after merger-related headlines. |
| Volatility | ATR near $2.5 | Recent average true range readings near $2.5 imply position sizing should allow normal daily movement. |
| Invalidation | Close below $104 | A decisive close below the 20-day and 200-day moving-average zone would invalidate the short-term trend-following setup. |
KMB AI trading strategy
The KMB AI trading strategy below is a research and risk framework, not personal financial advice. It combines defensive income analysis, merger-risk monitoring, and technical confirmation.
Watch whether KMB can hold above the $104 to $106 moving-average support area and push through $116 to $120 with volume confirmation.
Define the exit before entry. A close below $104 would signal that the rebound is losing trend support.
If KMB pulls back toward the low $100s without damage to sales growth, dividend coverage, or Kenvue close probability, compare the entry against yield and base-case scenario value.
Do not treat every staples pullback as safe. A break below the 50-day zone near $100 would require reassessing whether the market is pricing deal or earnings risk.
Track organic sales, volume-plus-mix, gross margin, pulp and freight costs, free cash flow, dividend coverage, debt, Kenvue regulatory approvals, and synergy milestones.
Refresh the scenario ranges after each earnings release and after any Kenvue financing, regulatory, or litigation update.
Investment research summary
Kimberly-Clark sells essential care categories that households, parents, caregivers, and institutions buy repeatedly. Customers pay for trust, convenience, absorbency, skin comfort, availability, and brand familiarity.
The moat comes from Huggies, Kleenex, Kotex, Depend, Cottonelle, and Scott brand equity, retail relationships, scale purchasing, manufacturing know-how, and category habit. It is real but not immune to private label or commodity cost pressure.
The thesis fails if KMB overpays for growth, Kenvue integration distracts management, debt reduces flexibility, Tylenol or talc litigation damages the combined company, or private label and pricing pressure compress margins.
Mike Hsu has been steering the Powering Care transformation, portfolio simplification, and the planned Kenvue acquisition. The key test is capital allocation, not just operating discipline.
Personal care and tissue are mature but durable categories. Growth depends on population, aging, premium care, emerging markets, product innovation, and affordability tiers rather than a fast technology adoption curve.
At about 18.0x TTM EPS and a 4.5% dividend yield, KMB is not priced like a high-growth stock. Margin of safety depends on free cash flow durability, deal execution, and whether investors keep rewarding defensive income.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KMB price | $114.74 on July 8, 2026 | StockAnalysis KMB financials and market data | July 8, 2026 |
| Market capitalization | $38.09 billion, calculated from $114.74 x 331.94 million shares | financial_rigor.py market-cap verification | July 8, 2026 |
| Shares outstanding | 331.94 million shares outstanding | StockAnalysis KMB statistics | July 8, 2026 |
| FY2025 revenue | $16.447 billion, cross-validated with StockAnalysis and Macrotrends | Kimberly-Clark 2025 Form 10-K | July 8, 2026 |
| FY2025 net income to common | $2.021 billion, cross-validated with StockAnalysis and Macrotrends | Kimberly-Clark 2025 Form 10-K | July 8, 2026 |
| FY2025 free cash flow | $1.639 billion on StockAnalysis standardized data; company cash flow less capital spending was about $1.639 billion | StockAnalysis KMB financials | July 8, 2026 |
| Q1 2026 sales and margin | $4.2 billion net sales, 36.8% gross margin, and $753 million operating profit | Kimberly-Clark Q1 2026 earnings release | July 8, 2026 |
| Cash and debt | $688 million cash and short-term investments and $7.168 billion total debt at FY2025; 10-K cash line was $701 million | StockAnalysis balance sheet and Kimberly-Clark 2025 Form 10-K | July 8, 2026 |
| Valuation metrics | 18.01x TTM PE, 20.75x P/FCF, 4.82% FCF yield, and 4.46% dividend yield from financial_rigor.py inputs | financial_rigor.py valuation verification | July 8, 2026 |
| Kenvue transaction status | Shareholders approved the transaction on January 29, 2026; closing expected in the second half of 2026 subject to regulatory approvals and customary conditions | Kimberly-Clark investor release | July 8, 2026 |
| Technical trend | 50-day SMA near $100.57, 200-day SMA near $104.83, and 14-day relative strength near 70 | Barchart KMB technical analysis | July 8, 2026 |
This page is an informational research tool only. It is not investment advice, financial advice, or a recommendation to buy, sell, or hold KMB. Forecasts are scenario-based estimates from available data and may be wrong. Always verify current filings, prices, dividend data, Kenvue transaction updates, and your own risk constraints before making decisions.
